AIM
AIM clinical trials: AIM ImmunoTech Inc.
Every trial on ClinicalTrials.gov where AIM ImmunoTech Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 9
- As lead sponsor
- 8
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AIM on the catalyst calendar · AIM registry changes
- Primary completion Feb 2031Sponsor estimatePhase 2NCT05494697Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCAIM ImmunoTech Inc. · Pancreatic CancerSuspendedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT00215813Ampligen in Chronic Fatigue SyndromeAIM ImmunoTech Inc. · Chronic Fatigue SyndromeTemporarily not availableAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2023ActualPhase 2NCT05592418Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID ConditionsAIM ImmunoTech Inc. · Post COVID-19 ConditionCompletedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2014ActualPhase 1/Phase 2NCT01591473Safety Study of FluMist With and Without AmpligenAIM ImmunoTech Inc. · Influenza, HumanTerminatedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2009ActualPhase 2NCT00215852A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ SubjectsAIM ImmunoTech Inc. · HIV InfectionsTerminatedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2006ActualPhase 2NCT00215826Study of Alferon® LDO (Low Dose Oral) in Normal VolunteersAIM ImmunoTech Inc. · Severe Acute Respiratory SyndromeCompletedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2004ActualPhase 3NCT00215800The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue SyndromeAIM ImmunoTech Inc. · Chronic Fatigue SyndromeCompletedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2006ActualPhase 2NCT00035893The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAARTAIM ImmunoTech Inc. · HIV SeropositivityCompletedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2005ActualPhase 2NCT00035581Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAARTAIM ImmunoTech Inc. · HIV SeropositivityTerminatedAIMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 2NCT07634094Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage...Kalinski, Pawel, MD, PhD · Ovarian CancerNot yet recruitingAIMCollaboratorNWBOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05927142Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic...Joachim Aerts, MD PhD · Metastatic Pancreatic CancerActive, not recruitingAIMCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 19, 2025ActualPhase 1/Phase 2NCT02432378Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC VaccinesRoswell Park Cancer Institute · Cancer of OvaryWithdrawnAIMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 2NCT03899987Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before SurgeryRoswell Park Cancer Institute · Prostate AdenocarcinomaActive, not recruitingAIMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2024ActualPhase 1/Phase 2NCT03734692Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerRobert Edwards · Ovarian Cancer RecurrentActive, not recruitingAIMCollaboratorMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2023ActualPhase 1/Phase 2NCT04379518Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer PatientsRoswell Park Cancer Institute · Hematopoietic and Lymphoid Cell NeoplasmTerminatedAIMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2016ActualPhase 1/Phase 2NCT01545141Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal CancerRoswell Park Cancer Institute · Colorectal CancerTerminatedAIMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2020ActualEarly Phase 1NCT03599453Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerRoswell Park Cancer Institute · Triple -Negative Breast CancerCompletedAIMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner